Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.50 |
| ▸ | DRD3 | P35462 | 8/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074420 | 1.00 | DRD2 (0.50) | DRD2DRD3HTR2A | |
| SCHEMBL4065018 | 0.85 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL4065022 | 0.85 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL4064593 | 0.85 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL4064585 | 0.85 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL4070858 | 0.85 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL4070856 | 0.85 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL4070312 | 0.85 | DRD2 (0.53) | DRD2DRD3HTR2A | |
| SCHEMBL4070309 | 0.85 | DRD2 (0.53) | DRD2DRD3HTR2A | |
| SCHEMBL4070656 | 0.84 | DRD2 (0.49) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725240-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | claimed |
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| EP-1725240-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | claimed |
| WO-2005094834-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | claimed |
| EP-1725240-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1725240-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005094834-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | CHRM3, CHRNG, CHRM2 | DRD2 969/4885DRD3 1530/4885HTR2A 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.